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The integration of cytogenetics and molecular genetics
into the histopathologic evaluation of soft tissue tumors has
certainly represented one of the major advances of the last
decade.1 It has not only served as both a validation and a
refinement of available classification schemes but has also
offered new diagnostic tools that have led to significant
improvement of diagnostic accuracy. Among mesenchymal
neoplasms, adipocytic tumor certainly represents an ideal
model of such integration. In fact, with the notable
exception of angiolipoma, most benign and malignant
adipocytic tumors harbor distinctive genetic aberration that
parallels their histomorphology. This has also proved true
for adipocytic malignancies. Liposarcoma is currently
subclassified genetically into three broad categories: (1)
well-differentiated (WD) liposarcoma/atypical lipomatous
tumors (ALT) and dedifferentiated liposarcoma featuring
aberrations of the 12q13–15 chromosome region; (2)
myxoid/round cell liposarcoma harboring a t(12;16) or
more rarely a t(12;22) reciprocal translocation, leading to
fusion of DDIT3 and FUS genes (95% of cases) or DDIT3
and EWS genes (5% of cases), respectively; and (3) pleo-
morphic liposarcoma showing (similarly to other
pleomorphic sarcomas) complex karyotypic aberrations.
With the advent (or the development) of more selective,
histotype-related, systemic treatments, accurate diagnosis
of mesenchymal tumors has become mandatory, as it not
only provides fundamental prognostic information but also
tends to determine treatment options.2,3 In the current issue
of Annals of Surgical Oncology both the diagnostic and
clinical impact of genetic observation is addressed by de
Vreeze et al.4
The diagnostic application of 12q13–15 aberration in the
differential diagnosis of well-differentiated/dediffer-
entiated liposarcoma dates back to the late 1990s, when
pathologists first started considering the use of MDM2 and
CDK4 increased protein expression (epiphenomenon of
gene amplification) as a possible novel diagnostic mar-
ker.5,6 Nuclear immunopositivity for MDM2 and CDK4
appears to be restricted to well-differentiated liposarcoma/
ALT, allowing separation from challenging examples of
benign lipomas. The same findings in the context of de-
differentiated liposarcoma permit its distinction from other
unrelated pleomorphic sarcomas that may also occur in the
retroperitoneum, and have also contributed to the decline
of malignant fibrous histiocytoma (MFH) as a meaningful
category.6,7 Even if immunohistochemistry in expert hands
appears to be acceptably reliable, fluorescence in situ
hybridization (FISH) analysis as well as quantitative
polymerase chain reaction (PCR)-based techniques can be
used to evaluate MDM2 gene status.8
Of course a few caveats need to be underscored in order
to avoid major pitfalls. First of all, MDM2 aberrations, as
well as DDIT3/FUS abnormalities, whatever the technique
used, should be evaluated in context with morphology.
Actually this represents a general principle whenever
dealing with rare form of cancers, for which diagnostic
expertise is certainly crucial but also hard to achieve
without access to a substantial number of cases. A second
point that has been raised is related to the fact that MDM2
and CDK4 represent cell-cycle regulators, the activation of
which may be not restricted to WD/dedifferentiated lipo-
sarcoma. While it is true that MDM2 gene amplification
has been reported in both malignant peripheral nerve
sheath tumors and undifferentiated (MFH) pleomorphic
sarcomas, in the context of adipocytic malignancies it
appears to be quite restricted to the well-differentiated/
dedifferentiated liposarcoma category. As a consequence
MDM2 analysis, as shown in the study of de Vreeze and
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colleagues, in addition to telling apart benign lipomas from
WD liposarcomas, can also be useful in discriminating
myxoid liposarcoma from well-differentiated liposarcoma
with myxoid change, as well as dedifferentiated liposar-
coma from pleomorphic liposarcoma.
However there certainly remain a number of cases in
which, despite the presence of a convincing morphology,
the expected genetic aberration is missing. We have also
encountered examples of classic myxoid liposarcoma or
WD liposarcoma lacking any genetic aberration. However,
it should be underlined that the mere absence of a given
genetic abnormality may simply reflect a technical failure.
As a consequence, even in the presence of state-of-the-art
molecular techniques, accurate morphologic assessment
should still represent the diagnostic mainstay. This
assumption is supported by two very simple reasons: (1) no
distinctive genetic aberration is present in 100% of cases of
a given tumor (i.e., PAX2 and PAX7 aberrations in alve-
olar rhabdomyosarcoma), and therefore a diagnosis can be
reliably rendered even if the associated genetic feature is
absent, and (2) the same genetic aberration may be present
in unrelated entities (i.e., ALK1 aberrations in anaplastic
large lymphoma and inflammatory myofibroblastic tumor
or EWSR1/CREB3/ATF1 aberrations in angiomatoid
fibrous histiocytoma and clear cell sarcoma), which would
be misdiagnosed if only genetic findings were to be taken
into account.
In conclusion, as underlined by the work of de Vreeze
et al., the analysis of genetic abnormalities associated with
adipocytic neoplasm is certainly a powerful tool that sig-
nificantly increases diagnostic accuracy. The current role of
genetic analysis is to complement and not to replace expert
morphologic observation. The combination of pathology
and genetics sets the rationale for appropriate clinical
decision-making and possibly leads to improvement of
outcome.
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